GLPBio

Signaling Pathways

Research Area, Signaling Pathways | GlpBio Life Science Products Suppliers

Read More about this category

The antibody-drug conjugate (ADC), a humanized or human monoclonal antibody conjugated with highly cytotoxic small molecules (payloads) through chemical linkers, is a novel therapeutic format and has great potential to make a paradigm shift in cancer chemotherapy. The three components of the ADC together give rise to a powerful oncolytic agent capable of delivering normally intolerable cytotoxins directly to cancer cells, which then internalize and release the cell-destroying drugs. At present, two ADCs, Adcetris and Kadcyla, have received regulatory approval with >40 others in clinical development.

ADCs are administered intravenously in order to prevent the mAb from being destroyed by gastric acids and proteolytic enzymes. The mAb component of the ADC enables it to circulate in the bloodstream until it finds and binds to tumor-specific cell surface antigens present on target cancer cells. Linker chemistry is an important determinant of the safety, specificity, potency and activity of ADCs. Linkers are designed to be stable in the blood stream (to conform to the increased circulation time of mAbs) and labile at the cancer site to allow rapid release of the cytotoxic drug. First generation ADCs made use of early cytotoxins such as the anthracycline, doxorubicin or the anti-metabolite/antifolate agent, methotrexate. Current cytotoxins have far greater potency and can be divided into three main groups: auristatins, maytansines and calicheamicins.

The development of site-specific conjugation methodologies for constructing homogeneous ADCs is an especially promising path to improving ADC design, which will open the way for novel cancer therapeutics.

References:

[1] Tsuchikama K, et al. Protein Cell. 2016 Oct 14. DOI:10.1007/s13238-016-0323-0.

[2] Peters C, et al. Biosci Rep. 2015 Jun 12;35(4). pii: e00225. doi: 10.1042/BSR20150089.

Research Areas

Products Related to Signaling Pathways(38391)

  • GC15914 structure
    GC15914CDK7-IN-1
    CAS: 1604810-84-5

    potent and selective CDK7 inhibitor

  • GC15921 structure
    GC15921A939572
    CAS: 1032229-33-6
    Purity: >99.50%

    A939572 es un inhibidor oral y específico de la stearoyl-CoA desaturase 1 (SCD1), con un valor de IC₅₀ de 6.3nM

  • GC16038 structure
    GC16038CZC-25146
    CAS: 1191911-26-8
    Purity: >98.50%

    CZC-25146 es un inhibidor de LRRK2 potente y activo por vÍa oral con valores de IC50 de 4,76 nM y 6,87 nM para LRRK2 de tipo salvaje y G2019S LRRK2, respectivamente.

  • GC16074 structure
    GC16074Misoprostol
    CAS: 59122-46-2
    Purity: >98%

    Misoprostol es un análogo de prostaglandina E1 (PGE1) activo por vía oral utilizado para prevenir úlceras gástricas,tratar abortos no autorizados,inducir el parto e inducir abortos espontáneos.

  • GC16189 structure
    GC16189BTS
    CAS: 1576-37-0
    Purity: >99.50%

    BTS (N-bencil-p-toluenosulfonamida) es un inhibidor potente y selectivo de la actividad ATPasa del subfragmento 1 (S1) de la miosina II del mÚsculo esquelético, con una IC50 de ~5 μM para la miosina S1 ATPasa estimulada por actina y Ca2+-.

  • GC16640 structure
    GC16640iCRT 14
    CAS: 677331-12-3
    Purity: >99.50%

    iCRT 14 es un nuevo inhibidor potente de la transcripciÓn sensible a β-catenina (CRT), con IC50 de 40,3 nM contra la luciferasa STF16 sensible a Wnt.

  • GC16645 structure
    GC16645Rabeprazole
    CAS: 117976-89-3
    Purity: >98%

    El rabeprazol (LY307640) es un inhibidor de la bomba de protones (IBP) de segunda generaciÓn que inactiva irreversiblemente la H+/K+-ATPasa gÁstrica.

  • GC17377 structure
    GC17377Clofibrate
    CAS: 637-07-0
    Purity: >98.00%

    El clofibrato es un agonista de PPAR, con EC50 de 50 μM, ~500 μM para PPARα y PPARγ murinos, y 55 μM, ~500 μM para PPARα y PPARγ humanos, respectivamente.

  • GC17469 structure
    GC174694-Aminopyridine
    CAS: 504-24-5
    Purity: >98.00%

    4-Aminopyridine is a non‑selective K⁺ channel blocker.

  • GC17517 structure
    GC17517Alcaftadine
    CAS: 147084-10-4
    Purity: >99.00%

    Alcaftadine (R89674) es un antagonista del receptor de histamina H1, que se usa para prevenir la irritaciÓn ocular provocada por la conjuntivitis alérgica.

  • GC17571 structure
    GC17571Ciclesonide
    CAS: 126544-47-6
    Purity: >99.00%

    La ciclesonida (RPR251526) es un glucocorticoide con una potente actividad antiinflamatoria.

  • GC17625 structure
    GC17625Lercanidipine
    CAS: 100427-26-7
    Purity: >98%

    La lercanidipina es un bloqueador de los canales de dihidropiridina-calcio de tercera generaciÓn lipofÍlico (DHP-CCB).

  • GC17643 structure
    GC17643Bilastine
    CAS: 202189-78-4
    Purity: >99.50%

    La bilastina es un antagonista selectivo de los receptores H1 de la histamina que se utiliza para el tratamiento de la rinoconjuntivitis alérgica y la urticaria.

  • GC17945 structure
    GC17945Metoprolol Succinate
    CAS: 98418-47-4
    Purity: >99.50%

    El succinato de metoprolol es un antagonista selectivo de los receptores adrenérgicos β1 activo por vÍa oral.

  • GC12305 structure
    GC12305GSK2141795
    CAS: 1047634-65-0
    Purity: >98.50%

    GSK2141795 (GSK2141795) es un inhibidor pan-Akt potente y selectivo con valores IC50 de 180/328/38 nM para Akt1/Akt2/Akt3, respectivamente.